A detailed history of Deutsche Bank Ag\ transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 533 shares of CADL stock, worth $2,270. This represents 0.0% of its overall portfolio holdings.

Number of Shares
533
Previous 68 683.82%
Holding current value
$2,270
Previous $0 Infinity%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$5.02 - $7.76 $2,334 - $3,608
465 Added 683.82%
533 $3,000
Q2 2024

Aug 14, 2024

BUY
$1.68 - $14.0 $114 - $952
68 New
68 $0

Others Institutions Holding CADL

About Candel Therapeutics, Inc.


  • Ticker CADL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,891,900
  • Market Cap $123M
  • Description
  • Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...
More about CADL
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.